<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647478</url>
  </required_header>
  <id_info>
    <org_study_id>P060224</org_study_id>
    <nct_id>NCT00647478</nct_id>
  </id_info>
  <brief_title>System-IGF-1 Pathway and Alzheimer's Disease</brief_title>
  <acronym>SIGAL</acronym>
  <official_title>A Multicenter Study to Assess Differences Between Circulating Levels of IGF-I and IGFBP-3 in Patients With Sporadic Late-onset Alzheimer's Disease and Control Elderly Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to assess the relationship between levels of IGF-I system components and cognitive
      status in patients with Alzheimer's disease (AD), in elderly subjects with normal cognitive
      function, and in patients with mild cognitive impairment (MCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AD is the most common cause of dementia. During aging, decline of biological brain functions
      due to a number of genetic and environmental factors facilitates the onset of AD. MCI
      includes prodromal AD.

      The identification of the risk factors for AD must be a priority in order to define the best
      therapeutic approach.

      Recent data support the notion that IGF-I pathway accounts for neuronal protection, with a
      dual effect, on both brain Aβ peptide and tau protein.

      This large, multicenter, prospective, observational, cross-sectional population-based study
      in 3 parallel groups (200 participants per group) is aimed to assess differences between
      IGF-I and IGFBP3 circulating levels and polymorphisms in AD patients and control elderly
      subjects, and in MCI patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating IGF-I and IGFBP-3 levels in AD patients and control elderly subjects at the time of assessment(T0).</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating IGF-I and IGFBP-3 levels</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphisms in IGF-I / IGFBP-3</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating IGF-I and IGFBP-3 levels and genetic polymorphisms in IGF-I / IGFBP-3 according to cognitive function.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">693</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Cognitive Function 1, Social</condition>
  <condition>Control With Normal Activities of Daily Living</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>AD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Control elderly subjects with normal cognitive function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>MCI</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood for plasma levels and polymorphisms in IGF1 system components
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulatory Elderly subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Caucasian patients after a comprehensive geriatric assessment and giving informed written
        consent.

        - In each arm :

          1. elderly subjects with normal cognitive function,

          2. patients with dementia of AD type (DSM-IV and NINCDS-ADRDA criteria),

          3. patients with MCI (European Consortium on Alzheimer's Disease, EADC).

        Exclusion Criteria:

        Non AD dementia Major depression Use of anticholinesterase agent All diseases or major
        sensory deficits or any condition that might interfere with cognitive assessment and study
        objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Hanon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Broca Hospital Memory Clinic (CMRR)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Murialdo G, Barreca A, Nobili F, Rollero A, Timossi G, Gianelli MV, Copello F, Rodriguez G, Polleri A. Relationships between cortisol, dehydroepiandrosterone sulphate and insulin-like growth factor-I system in dementia. J Endocrinol Invest. 2001 Mar;24(3):139-46.</citation>
    <PMID>11314741</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin-like Growth Factor</keyword>
  <keyword>Insulin-like Growth Factor binding protein 3</keyword>
  <keyword>Insulin-like Growth Factor-I system component levels</keyword>
  <keyword>Insulin-like Growth Factor-I polymorphism</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Normal cognitive function</keyword>
  <keyword>Observational cross sectional study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

